<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00185380</url>
  </required_header>
  <id_info>
    <org_study_id>91412</org_study_id>
    <secondary_id>2004-002291-42</secondary_id>
    <secondary_id>308901</secondary_id>
    <nct_id>NCT00185380</nct_id>
  </id_info>
  <brief_title>Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS)</brief_title>
  <official_title>Multi-center, Open, Randomized, Dose Finding Phase II Study to Investigate Ultra Low Dose Levonorgestrel Contraceptive Intrauterine Systems (LCS) Releasing Different Amounts of Levonorgestrel Compared to MIRENA in Nulliparous and Parous Women in Need of Contraception.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if drug doses lower than the one released from
      Mirena® would be as effective for contraception as Mirena®. Subjects participating in the
      study will be randomly assigned to be inserted with any of the three different intrauterine
      systems (IUSs). The IUSs are nearly alike except that the amount of hormone released from
      them is different.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been
      renamed to Bayer Schering Pharma AG, Germany.

      Bayer Schering Pharma AG, Germany is the sponsor of the trial.

      Although the title of the study describes &quot;open&quot;, it was in fact single-blinded.

      Issues on side effects are addressed in the Adverse Event section.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pearl Index</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The Pearl Index (PI) is defined as the number of pregnancies per 100 woman years. The 3-year PI was obtained by dividing the number of pregnancies that occurred during the first three years of treatment by the time (in 100 women years) that the women were under risk of getting pregnant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Total or Partial Expulsions</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The numbers of subjects with partial or total IUS expulsions (device displaced from its correct position within the uterus) were to be given by treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Pattern by 90-day Reference Periods - Reference Period 1</measure>
    <time_frame>day 1 to day 90</time_frame>
    <description>Subjects kept a bleeding diary and recorded any bleeding every day by category: none, spotting, light, normal or heavy. Any missing data were obtained by direct questioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Pattern by 90-day Reference Periods - Reference Period 2</measure>
    <time_frame>day 91 to day 180</time_frame>
    <description>Subjects kept a bleeding diary and recorded any bleeding every day by category: none, spotting, light, normal or heavy. Any missing data were obtained by direct questioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Pattern by 90-day Reference Periods - Reference Period 3</measure>
    <time_frame>day 181 to day 270</time_frame>
    <description>Subjects kept a bleeding diary and recorded any bleeding every day by category: none, spotting, light, normal or heavy. Any missing data were obtained by direct questioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Pattern by 90-day Reference Periods - Reference Period 4</measure>
    <time_frame>day 271 to day 360</time_frame>
    <description>Subjects kept a bleeding diary and recorded any bleeding every day by category: none, spotting, light, normal or heavy. Any missing data were obtained by direct questioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Pattern by 90-day Reference Periods - Reference Period 12</measure>
    <time_frame>day 991 to day 1080</time_frame>
    <description>Subjects kept a bleeding diary and recorded any bleeding every day by category: none, spotting, light, normal or heavy. Any missing data were obtained by direct questioning.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">742</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>LCS12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 12 microg/24h in vitro</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCS16</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 16 microg/24h in vitro</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IUS20 (Mirena)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levonorgestrel intrauterine system (IUS) releasing 20 microg/24h in vitro</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel IUS (BAY86-5028, G04209B)</intervention_name>
    <description>Levonorgestrel intrauterine contraception system (IUS) releasing 12 microg/24 h in vitro, to be used for three years</description>
    <arm_group_label>LCS12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel IUS (BAY86-5028, G04209C)</intervention_name>
    <description>Levonorgestrel intrauterine contraception system (IUS) releasing 16 microg/24 h in vitro, to be used for three years</description>
    <arm_group_label>LCS16</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel IUS (Mirena, BAY86-5028)</intervention_name>
    <description>Levonorgestrel Intrauterine contraception system (IUS) releasing 20 microg/24 h to be used for three years</description>
    <arm_group_label>IUS20 (Mirena)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with or without children and good general health and in need of contraception.

          -  Regular menstrual cycle without hormonal contraceptives.

        Exclusion Criteria:

          -  Pregnant or lactating.

          -  Last delivery or abortion less than 12 weeks ago.

          -  Previous pregnancies outside the womb.

          -  Previous pelvic infections.

          -  Abnormal bleeding.

          -  Abnormal uterine cavity.

          -  Climacteric signs.

          -  Genital cancer.

          -  Liver diseases.

          -  Alcoholism or drug abuse.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Espoo</city>
        <zip>02100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Joensuu</city>
        <zip>80100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jyväskylä</city>
        <zip>40620</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kotka</city>
        <zip>48100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuopio</city>
        <zip>70110</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lahti</city>
        <zip>15110</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oulu</city>
        <zip>90100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oulu</city>
        <zip>90570</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <zip>20540</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bekescsaba</city>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Drammen</city>
        <zip>3001</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elverum</city>
        <zip>2403</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kolbotn</city>
        <zip>1411</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Larvik</city>
        <zip>3264</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <zip>0309</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trondheim</city>
        <zip>7014</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göteborg</city>
        <zip>411 35</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huddinge</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalmar</city>
        <zip>39231</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Luleå</city>
        <zip>972 33</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norrköping</city>
        <zip>602 22</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>S-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Umeå</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Örebro</city>
        <zip>701 46</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesterfield</city>
        <state>Derbyshire</state>
        <zip>S40 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S1 2PJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesterfield</city>
        <zip>S40 1SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Hungary</country>
    <country>Norway</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Lithuania</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <results_reference>
    <citation>Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril. 2012 Mar;97(3):616-22.e1-3. doi: 10.1016/j.fertnstert.2011.12.003. Epub 2012 Jan 4.</citation>
    <PMID>22222193</PMID>
  </results_reference>
  <results_reference>
    <citation>Apter D, Gemzell-Danielsson K, Hauck B, Rosen K, Zurth C. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. Fertil Steril. 2014 Jun;101(6):1656-62.e1-4. doi: 10.1016/j.fertnstert.2014.03.004. Epub 2014 Apr 14.</citation>
    <PMID>24726226</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>December 10, 2009</results_first_submitted>
  <results_first_submitted_qc>February 22, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 10, 2010</results_first_posted>
  <last_update_submitted>May 15, 2015</last_update_submitted>
  <last_update_submitted_qc>May 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Parous or nulliparous women in good general health and in need of contraception were recruited from medical clinics between April and Nov 2005.</recruitment_details>
      <pre_assignment_details>Most screening failures were in-/exclusion criteria not met and over-screening. Randomized: 742 women, Treated: 738 women. Full analysis set (FAS), safety analysis set (SAF) and per protocol analysis set (PPS) were identical (738 subjects).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LCS12</title>
          <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 12 microg/24h in vitro</description>
        </group>
        <group group_id="P2">
          <title>LCS16</title>
          <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 16 microg/24h in vitro</description>
        </group>
        <group group_id="P3">
          <title>IUS20 (Mirena)</title>
          <description>Levonorgestrel intrauterine system (IUS) releasing 20 microg/24h in vitro</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="246"/>
                <participants group_id="P3" count="256"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Subjects Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="239"/>
                <participants group_id="P2" count="245"/>
                <participants group_id="P3" count="254"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="174"/>
                <participants group_id="P2" count="174"/>
                <participants group_id="P3" count="182"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="74"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed insertion</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Planned pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No need for contraception</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Could not attend visits</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>personal reason</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LCS12</title>
          <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 12 microg/24h in vitro</description>
        </group>
        <group group_id="B2">
          <title>LCS16</title>
          <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 16 microg/24h in vitro</description>
        </group>
        <group group_id="B3">
          <title>IUS20 (Mirena)</title>
          <description>Levonorgestrel intrauterine system (IUS) releasing 20 microg/24h in vitro</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="239"/>
            <count group_id="B2" value="245"/>
            <count group_id="B3" value="254"/>
            <count group_id="B4" value="738"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.2" spread="5.44"/>
                    <measurement group_id="B2" value="32.1" spread="5.31"/>
                    <measurement group_id="B3" value="32.0" spread="5.21"/>
                    <measurement group_id="B4" value="32.1" spread="5.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Whilst 742 subjects were randomized, only 738 were treated.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="239"/>
                    <measurement group_id="B2" value="245"/>
                    <measurement group_id="B3" value="254"/>
                    <measurement group_id="B4" value="738"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pearl Index</title>
        <description>The Pearl Index (PI) is defined as the number of pregnancies per 100 woman years. The 3-year PI was obtained by dividing the number of pregnancies that occurred during the first three years of treatment by the time (in 100 women years) that the women were under risk of getting pregnant.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>All randomized women with a successful insertion were analyzed according to the treatment actually received and were included in the FAS, which was the set used for all safety and efficacy analyses. The PPS was identical to the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 12 microg/24h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 16 microg/24h in vitro</description>
          </group>
          <group group_id="O3">
            <title>IUS20 (Mirena)</title>
            <description>Levonorgestrel intrauterine system (IUS) releasing 20 microg/24h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Pearl Index</title>
          <description>The Pearl Index (PI) is defined as the number of pregnancies per 100 woman years. The 3-year PI was obtained by dividing the number of pregnancies that occurred during the first three years of treatment by the time (in 100 women years) that the women were under risk of getting pregnant.</description>
          <population>All randomized women with a successful insertion were analyzed according to the treatment actually received and were included in the FAS, which was the set used for all safety and efficacy analyses. The PPS was identical to the FAS.</population>
          <units>Number per 100 women years</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" lower_limit="0.00" upper_limit="0.93"/>
                    <measurement group_id="O2" value="0.82" lower_limit="0.27" upper_limit="1.92"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Total or Partial Expulsions</title>
        <description>The numbers of subjects with partial or total IUS expulsions (device displaced from its correct position within the uterus) were to be given by treatment.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>The analysis was performed on the FAS (all subjects who had an IUS inserted).</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 12 microg/24h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 16 microg/24h in vitro</description>
          </group>
          <group group_id="O3">
            <title>IUS20 (Mirena)</title>
            <description>Levonorgestrel intrauterine system (IUS) releasing 20 microg/24h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Total or Partial Expulsions</title>
          <description>The numbers of subjects with partial or total IUS expulsions (device displaced from its correct position within the uterus) were to be given by treatment.</description>
          <population>The analysis was performed on the FAS (all subjects who had an IUS inserted).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>total expulsion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>partial expulsion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Pattern by 90-day Reference Periods - Reference Period 1</title>
        <description>Subjects kept a bleeding diary and recorded any bleeding every day by category: none, spotting, light, normal or heavy. Any missing data were obtained by direct questioning.</description>
        <time_frame>day 1 to day 90</time_frame>
        <population>The analysis was performed on the FAS (all subjects with an insertion) and included subjects with bleeding or spotting or both.</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 12 microg/24h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 16 microg/24h in vitro</description>
          </group>
          <group group_id="O3">
            <title>IUS20 (Mirena)</title>
            <description>Levonorgestrel intrauterine system (IUS) releasing 20 microg/24h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Pattern by 90-day Reference Periods - Reference Period 1</title>
          <description>Subjects kept a bleeding diary and recorded any bleeding every day by category: none, spotting, light, normal or heavy. Any missing data were obtained by direct questioning.</description>
          <population>The analysis was performed on the FAS (all subjects with an insertion) and included subjects with bleeding or spotting or both.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="241"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of bleeding days (light, normal or heavy)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="10.1"/>
                    <measurement group_id="O2" value="15.4" spread="12.2"/>
                    <measurement group_id="O3" value="14.3" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of bleeding/spotting days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.9" spread="18.7"/>
                    <measurement group_id="O2" value="39.2" spread="19.7"/>
                    <measurement group_id="O3" value="36.6" spread="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of spotting only days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="14.1"/>
                    <measurement group_id="O2" value="23.8" spread="12.9"/>
                    <measurement group_id="O3" value="22.2" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Pattern by 90-day Reference Periods - Reference Period 2</title>
        <description>Subjects kept a bleeding diary and recorded any bleeding every day by category: none, spotting, light, normal or heavy. Any missing data were obtained by direct questioning.</description>
        <time_frame>day 91 to day 180</time_frame>
        <population>The analysis was performed on the FAS (all subjects with an insertion) and included subjects with bleeding or spotting or both.</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 12 microg/24h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 16 microg/24h in vitro</description>
          </group>
          <group group_id="O3">
            <title>IUS20 (Mirena)</title>
            <description>Levonorgestrel intrauterine system (IUS) releasing 20 microg/24h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Pattern by 90-day Reference Periods - Reference Period 2</title>
          <description>Subjects kept a bleeding diary and recorded any bleeding every day by category: none, spotting, light, normal or heavy. Any missing data were obtained by direct questioning.</description>
          <population>The analysis was performed on the FAS (all subjects with an insertion) and included subjects with bleeding or spotting or both.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of bleeding days (light, normal or heavy)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="8.0"/>
                    <measurement group_id="O2" value="7.7" spread="8.0"/>
                    <measurement group_id="O3" value="7.6" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of bleeding/spotting days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" spread="14.3"/>
                    <measurement group_id="O2" value="21.8" spread="14.3"/>
                    <measurement group_id="O3" value="21.8" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of spotting only days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="10.3"/>
                    <measurement group_id="O2" value="14.1" spread="9.8"/>
                    <measurement group_id="O3" value="14.2" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Pattern by 90-day Reference Periods - Reference Period 3</title>
        <description>Subjects kept a bleeding diary and recorded any bleeding every day by category: none, spotting, light, normal or heavy. Any missing data were obtained by direct questioning.</description>
        <time_frame>day 181 to day 270</time_frame>
        <population>The analysis was performed on the FAS (all subjects with an insertion) and included subjects with bleeding or spotting or both.</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 12 microg/24h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 16 microg/24h in vitro</description>
          </group>
          <group group_id="O3">
            <title>IUS20 (Mirena)</title>
            <description>Levonorgestrel intrauterine system (IUS) releasing 20 microg/24h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Pattern by 90-day Reference Periods - Reference Period 3</title>
          <description>Subjects kept a bleeding diary and recorded any bleeding every day by category: none, spotting, light, normal or heavy. Any missing data were obtained by direct questioning.</description>
          <population>The analysis was performed on the FAS (all subjects with an insertion) and included subjects with bleeding or spotting or both.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of bleeding days (light, normal or heavy)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="7.3"/>
                    <measurement group_id="O2" value="5.4" spread="6.9"/>
                    <measurement group_id="O3" value="5.3" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of bleeding/spotting days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" spread="12.9"/>
                    <measurement group_id="O2" value="16.7" spread="12.6"/>
                    <measurement group_id="O3" value="16.8" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of spotting only days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="9.3"/>
                    <measurement group_id="O2" value="11.3" spread="8.4"/>
                    <measurement group_id="O3" value="11.5" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Pattern by 90-day Reference Periods - Reference Period 4</title>
        <description>Subjects kept a bleeding diary and recorded any bleeding every day by category: none, spotting, light, normal or heavy. Any missing data were obtained by direct questioning.</description>
        <time_frame>day 271 to day 360</time_frame>
        <population>The analysis was performed on the FAS (all subjects with an insertion) and included subjects with bleeding or spotting or both.</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 12 microg/24h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 16 microg/24h in vitro</description>
          </group>
          <group group_id="O3">
            <title>IUS20 (Mirena)</title>
            <description>Levonorgestrel intrauterine system (IUS) releasing 20 microg/24h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Pattern by 90-day Reference Periods - Reference Period 4</title>
          <description>Subjects kept a bleeding diary and recorded any bleeding every day by category: none, spotting, light, normal or heavy. Any missing data were obtained by direct questioning.</description>
          <population>The analysis was performed on the FAS (all subjects with an insertion) and included subjects with bleeding or spotting or both.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="218"/>
                <count group_id="O3" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of bleeding days (light, normal or heavy)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="6.7"/>
                    <measurement group_id="O2" value="4.7" spread="6.4"/>
                    <measurement group_id="O3" value="4.2" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of bleeding/spotting days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="11.4"/>
                    <measurement group_id="O2" value="15.0" spread="11.6"/>
                    <measurement group_id="O3" value="15.2" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of spotting only days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="8.5"/>
                    <measurement group_id="O2" value="10.2" spread="7.9"/>
                    <measurement group_id="O3" value="11.0" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Pattern by 90-day Reference Periods - Reference Period 12</title>
        <description>Subjects kept a bleeding diary and recorded any bleeding every day by category: none, spotting, light, normal or heavy. Any missing data were obtained by direct questioning.</description>
        <time_frame>day 991 to day 1080</time_frame>
        <population>The analysis was performed on the FAS (all subjects with an insertion) and included subjects with bleeding or spotting or both.</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 12 microg/24h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 16 microg/24h in vitro</description>
          </group>
          <group group_id="O3">
            <title>IUS20 (Mirena)</title>
            <description>Levonorgestrel intrauterine system (IUS) releasing 20 microg/24h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Pattern by 90-day Reference Periods - Reference Period 12</title>
          <description>Subjects kept a bleeding diary and recorded any bleeding every day by category: none, spotting, light, normal or heavy. Any missing data were obtained by direct questioning.</description>
          <population>The analysis was performed on the FAS (all subjects with an insertion) and included subjects with bleeding or spotting or both.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="169"/>
                <count group_id="O3" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of bleeding days (light, normal or heavy)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="6.0"/>
                    <measurement group_id="O2" value="3.0" spread="4.5"/>
                    <measurement group_id="O3" value="1.9" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of bleeding/spotting days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="10.7"/>
                    <measurement group_id="O2" value="10.6" spread="9.3"/>
                    <measurement group_id="O3" value="8.8" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of spotting only days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="8.4"/>
                    <measurement group_id="O2" value="7.7" spread="6.9"/>
                    <measurement group_id="O3" value="6.9" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>An additional pregnancy was not recorded as an SAE.</desc>
      <group_list>
        <group group_id="E1">
          <title>LCS12</title>
          <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 12 microg/24h in vitro</description>
        </group>
        <group group_id="E2">
          <title>LCS16</title>
          <description>Levonorgestrel intrauterine contraceptive system (LCS) releasing 16 microg/24h in vitro</description>
        </group>
        <group group_id="E3">
          <title>IUS20 (Mirena)</title>
          <description>Levonorgestrel intrauterine system (IUS) releasing 20 microg/24h in vitro</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Gastroduodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Encephalitis herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Skull fractured base</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Phaeochromocytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Post-traumatic epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Adhesiolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Mammoplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="187" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="198" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="218" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="82" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast discomfort</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Seborrhoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor is interested in the publication of the results of every study. As some of the information concerning the study drug and the sponsor's development activities may be strictly confidential, any publication manuscript (including conference contributions, etc.) must first be reviewed by the sponsor before its submission or presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

